Statin-fibrate combination for mixed dyslipidaemia: a limited option?
Abstract A growing body of evidence suggests that targeting low-density lipoprotein cholesterol is not enough and that a substantial residual risk remains despite aggressive statin treatment, particularly in patients with mixed dyslipidemia. Statin plus fibrate combination results in a more effective control of several lipid parameters than either monotherapy with a safety profile similar to both monotherapies. Therefore, this combination might represent a therapeutic option for selected patients with mixed dyslipidemia. However, the clinical benefit of statin/fibrate combination has only been observed in small subgroup analyses and more data are needed before a wider implementation is recommended in everyday clinical practice.
Athyros
Vasilios G
VG
Tziomalos
Konstantinos
K
Karagiannis
Asterios
A
Mikhailidis
Dimitri P
DP
D002755:Choice Behavior; D004338:Drug Combinations; D050171:Dyslipidemias / Q000188:drug therapy*; D058607:Fibric Acids / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D000960:Hypolipidemic Agents / Q000008:administration & dosage / Q000009:adverse effects
D004338:Drug Combinations; D058607:Fibric Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents